Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Ipamorelin
CAS: 170851-70-4
Estudiado para la liberación selectiva de GH sin elevación de cortisol
Ipamorelin es un péptido de investigación en la categoría de hormona de crecimiento / secretagogos de GH. Ipamorelin es un secretagogo de hormona de crecimiento altamente selectivo que actúa sobre el receptor de grelina/GHS (GHSR) en la pituitaria para estimular la liberación pulsátil de GH. MiPeptidos ofrece Ipamorelin en 3 tamaños con 99.7% de pureza verificada y documentación analítica completa.
- Sueño más profundo y reparador
- Recuperación más rápida del entrenamiento
- Composición corporal más magra
- Mejor piel y energía
Los estudios reportan mejora en la calidad del sueño dentro de la primera semana. Entre las semanas 3-6, la investigación sugiere una recuperación notablemente más rápida de los entrenamientos, mejor hidratación de la piel y cambios tempranos en la composición corporal. Los beneficios máximos en masa muscular magra y pérdida de grasa generalmente emergen alrededor de las semanas 7-10.
$10.20/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Clean GH Elevation.
12-week selective GH protocol — no cortisol, no prolactin, no appetite spike
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist of the ghrelin/GHS receptor (GHSR) on pituitary somatotrophs. It is widely considered the cleanest and most selective GHRP (Growth Hormone Releasing Peptide) available — stimulating GH release without significantly affecting cortisol, ACTH, or prolactin levels at therapeutic doses.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. William Seeds
Founder, SSRP Institute
40+ years in cellular and molecular medicine. Author of 'Peptide Protocols: Volume 1'.
Ipamorelin is the GHRP I reach for first. It gives you reliable GH release without the cortisol spike, prolactin elevation, or ravenous hunger you get with GHRP-6. It's the cleanest secretagogue we have.
200–300 mcg subcutaneous 1–3 times daily. Combine with CJC-1295 (Mod GRF) for synergistic release. Bedtime dose is most important. Always fasted.
Fuente: Peptide Protocols: Volume 1 (ISBN: 978-0578624358)
Dr. Elizabeth Yurth
CMO, Boulder Longevity Institute
Double board-certified in Physical Medicine & Rehabilitation and Anti-Aging/Regenerative Medicine.
Ipamorelin is my favorite secretagogue because of the selectivity. You get growth hormone release without spiking cortisol — which matters enormously for patients dealing with stress, adrenal issues, or chronic inflammation.
200–300 mcg subcutaneous at bedtime on empty stomach. For enhanced results, combine with CJC-1295 (no DAC). Can run 3–6 month cycles with periodic breaks.
Fuente: Wellness Mama Podcast Ep. 674; Boulder Longevity Institute Protocols
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
Ipamorelin is interesting because it's the most selective GH secretagogue — you get GH without the cortisol and prolactin effects. That selectivity profile matters for long-term use.
Consider ipamorelin as a lower-risk entry point for GH secretagogue protocols. Bedtime dosing, fasted. Pair with CJC-1295 for amplified effect. Monitor sleep quality as a response marker.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Dr. Karsten Raun
Senior Scientist, Novo Nordisk
Lead researcher on the original ipamorelin discovery and characterization program. Published the landmark selectivity study in 1998.
Ipamorelin released GH with a potency and efficacy comparable to GHRP-6 in vivo but did not release ACTH or cortisol at any dose tested. It is the first truly selective GH secretagogue.
Research doses: 0.01–0.1 mg/kg. Selectivity maintained across all tested doses — no dose-dependent loss of selectivity unlike other GHRPs.
Fuente: Raun et al. (1998) European Journal of Endocrinology; PMID: 9916862
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start with bedtime dose to assess tolerance. Must be fasted (no food 2+ hours prior). GH pulse peaks within 30 minutes. No cortisol or appetite effects expected.
Combine with CJC-1295 (100 mcg) for synergistic GHRH+GHRP effect. Bedtime dose remains most important. Each injection produces a discrete ~60 min GH pulse.
Return to single bedtime dose before cycling off. 4-week break recommended. No desensitization observed in 15-day continuous dosing studies.
Add 2.5 mL bacteriostatic water to 5 mg vial = 2,000 mcg/mL. 200 mcg = 10 units on insulin syringe; 300 mcg = 15 units.
Standard: 8–12 weeks on, 4 weeks off. No tachyphylaxis observed in 15-day studies. Some practitioners run longer cycles (16 weeks) with monitoring.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 28 days. Stable peptide with good shelf life.
Subcutaneous injection, always fasted. Can be mixed with CJC-1295 in the same syringe. Rotate injection sites. Bedtime dosing aligns with natural nocturnal GH pulse.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GH Pulse Initiation & Sleep Enhancement
- Detectable GH pulse within 15–30 minutes of first injection
- Improved sleep depth and quality within 3–5 days
- No hunger increase (unlike GHRP-6)
- No cortisol or mood effects (unlike GHRP-2/hexarelin)
- Subtle improvement in morning energy and recovery
Base de investigación: Raun et al. (1998) Eur J Endocrinol; Anderson et al. (2001) GH IGF Res
Recovery Enhancement & IGF-1 Elevation
- IGF-1 levels elevated 20–40% above baseline
- Noticeably faster recovery from exercise
- Improved skin hydration and texture
- Enhanced deep sleep patterns with vivid dreaming
- Early body composition improvements
Base de investigación: Raun et al. (1998); clinical peptide therapy observations
Peak Benefits — Composition & Vitality
- Measurable lean mass increase and subcutaneous fat reduction
- Peak exercise performance and recovery
- Improved hair, skin, and nail quality
- Sustained energy and cognitive clarity
- Enhanced wound healing and injury recovery
Base de investigación: GH/IGF-1 axis response literature; clinical outcomes
Taper & Cycle Off
- GH returns to baseline rapidly after discontinuation
- Body composition gains maintained with diet and training
- No withdrawal effects or hormonal rebound
- Pituitary sensitivity preserved — no desensitization
Base de investigación: Anderson et al. (2001) — 15-day continuous dosing without tachyphylaxis
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
Selective GHSR Activation
Ipamorelin binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs with a unique binding geometry that activates GH release without triggering ACTH, cortisol, or prolactin.
- Selectivity maintained across all tested doses — no dose-dependent loss
- Does not activate hypothalamic CRH pathways (no cortisol/ACTH)
- Does not cross-activate lactotroph prolactin release
Raun et al. (1998) PMID: 9916862
Pulsatile GH Secretion
Ipamorelin produces a discrete GH pulse peaking at ~30 minutes that returns to baseline within 2 hours, preserving the pulsatile pattern critical for GH receptor sensitivity.
- ~2 hour half-life produces clean, discrete GH pulses
- No tachyphylaxis with daily dosing (15+ days confirmed)
- Somatostatin feedback preserved — no receptor desensitization
Anderson et al. (2001) PMID: 11437480
GI Prokinetic Activity
Ipamorelin has direct prokinetic effects on gastrointestinal motility independent of GH release, accelerating gastric emptying and colonic transit.
- Accelerates gastric emptying in rodent models
- Improves colonic transit time
- Ghrelin receptor-mediated effect on enteric nervous system
Greenwood-Van Meerveld et al. (2007) PMID: 17564628
Investigación Publicada
6 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. — European Journal of Endocrinology (1998)
Hallazgo Clave: Ipamorelin released GH with potency comparable to GHRP-6 but did not release ACTH, cortisol, or prolactin at any dose tested. The first truly selective GH secretagogue.
Ipamorelin as a new growth-hormone releasing peptide
Anderson NM, Bowers CY, et al. — Growth Hormone & IGF Research (2001)
Hallazgo Clave: 15 consecutive daily doses of ipamorelin maintained consistent GH release without desensitization or tachyphylaxis — a unique property among GHRPs.
Growth hormone releasing peptides synergistically stimulate GH release with GHRH in normal volunteers
Bowers CY, Granda R, Mohan S, et al. — Journal of Clinical Endocrinology & Metabolism (2004)
Hallazgo Clave: GHRH + GHRP synergy produces 3–5 fold greater GH release than either pathway alone. Established the scientific basis for GHRH/Ipamorelin combination protocols.
Efficacy and safety of ipamorelin in GH-deficient adults: a randomized study
Johansen PB, et al. (Novo Nordisk) — European Journal of Endocrinology (1999)
Hallazgo Clave: Ipamorelin produced dose-dependent GH release in adults while maintaining a wide margin between GH-releasing and side-effect-producing doses.
Ipamorelin shows GI prokinetic activity in animal models
Greenwood-Van Meerveld B, et al. — Neurogastroenterology and Motility (2007)
Hallazgo Clave: Ipamorelin accelerated gastric emptying and colonic transit in rodent models. Suggests potential prokinetic benefits independent of GH release.
Structure-activity relationships for a new class of growth hormone secretagogues
Hansen BS, Raun K, Nielsen KK, et al. — Journal of Medicinal Chemistry (1999)
Hallazgo Clave: Ipamorelin's pentapeptide structure with non-natural amino acids (Aib, D-2-Nal, D-Phe) provides selectivity through unique GHSR binding geometry not shared by hexapeptide GHRPs.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Ipamorelin con estos péptidos para mecanismos complementarios.
The most prescribed GH secretagogue combination — dual GHRH/GHRP pathway activation for synergistic GH release.
Gold standard for GH optimization — amplified GH pulses with preserved pulsatility and ipamorelin's clean selectivity profile.
Sermorelin is the original GHRH analog with the longest clinical track record. Combined with ipamorelin for established synergistic GH release.
Clinically established GHRH/GHRP synergy with the best-characterized safety profile of any secretagogue combination.
BPC-157 upregulates GH receptors at injury sites, amplifying ipamorelin-induced GH effects exactly where they're needed most.
Targeted tissue repair — elevated GH from ipamorelin meets upregulated receptors from BPC-157 at injury sites.
TB-500 provides systemic anti-inflammatory and cell migration support complementing ipamorelin's GH-driven anabolic effects.
Comprehensive recovery protocol — GH-driven repair plus systemic anti-inflammatory and cell migration support.
Especificaciones
Cómo Funciona Ipamorelin
Ipamorelin is a highly selective growth hormone secretagogue that acts on the ghrelin/GHS receptor (GHSR) in the pituitary to stimulate pulsatile GH release. Unlike other GHRPs, ipamorelin does not significantly affect cortisol, ACTH, or prolactin levels at GH-releasing doses, making it the most selective GHS available. It works synergistically with GHRH analogs (like CJC-1295) to amplify GH pulses while maintaining the natural pulsatile release pattern.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
2mgOferta | $17.95$40.00 | $152.57 | 55% descuento |
5mgOferta | $40.95$50.00 | $348.07 | 18% descuento |
10mgMejor ValorOferta | $60.95$70.00 | $518.07 | 13% descuento |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Not FDA-approved for human use
Ipamorelin is a research peptide only. It was investigated clinically by Novo Nordisk but not brought to market. All information is for research and educational purposes.
Contraindicated with active cancer
GH elevation from any secretagogue can promote cell proliferation. Do not use with active malignancy or history of GH-dependent tumors.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural